Vir Biotechnology Inc (VIR)
Solvency ratios
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt-to-assets ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-capital ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-equity ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial leverage ratio | 1.21 | 1.22 | 1.24 | 1.35 | 1.35 | 1.25 | 1.34 | 1.44 | 1.36 | 1.38 | 1.43 | 1.74 | 1.28 | 1.16 | 1.19 |
Based on the data provided for Vir Biotechnology Inc, the solvency ratios paint a picture of a company with very low levels of debt relative to its assets, capital, and equity across all quarters from Q1 2022 to Q4 2023. The debt-to-assets, debt-to-capital, and debt-to-equity ratios are consistently reported as 0.00, indicating that the company has effectively zero debt obligations in relation to its total assets, capital, and equity.
However, there is a trend of increasing financial leverage ratios over the quarters, from 1.21 in Q4 2022 to 1.44 in Q1 2022. This suggests that the company's reliance on debt to finance its operations or investments has been gradually increasing over time, potentially leading to higher financial risk.
Overall, while the low debt ratios indicate a strong solvency position with minimal financial risk in terms of debt obligations, the increasing financial leverage ratio raises some concerns about the company's debt management and the potential impact on its financial stability in the future. It would be important for investors and stakeholders to monitor the company's debt levels and leverage ratio closely to ensure sustainable financial health.
Coverage ratios
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Interest coverage | -1,431.60 | -69.87 | -16.28 | -8.27 | 21.18 | 52.53 | 64.46 | 4,106.22 | — | — | — | — | — | — | — |
I'm sorry, but without specific data on interest expenses and earnings before interest and taxes (EBIT) for each quarter, it is not possible to calculate the interest coverage ratio for Vir Biotechnology Inc. Interest coverage ratio is a financial metric used to assess a company's ability to pay its interest obligations on outstanding debt. If you provide the necessary information on interest expenses and EBIT for the periods mentioned, I would be able to calculate and analyze the interest coverage ratio for a more comprehensive assessment of Vir Biotechnology Inc's financial health.